Medical University Innsbruck   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Innsbruck Austria (2004)

Organization Overview

First Clinical Trial
2004
NCT00003984
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Department for Neurology, Medical University Innsbruck | Department of Anesthesia and Intensive Care | Department of Biological Psychiatry, Innsbruck University Clinics | Department of Trauma Surgery, Medical University of Innsbruck, Austria | Dr. Claudia Bösmüller | Dr. Gerhard Pölzl | General and Surgical Intensive Care Medicine, Medical University Innsbruck | Georg.Pall@i-med.ac.at | Innsbruck Medical University | Innsbruck Medical University, Dep. for Anaesthesia and Crit. Care Management | Innsbruck Medical University, Innsbruck, Austria | Medical University for Surgery and Transplantation, Innsbruck | Medical University Innsbruck | Medical University Innsbruck, Departement of Anaesthesiology and Intensive Care | Medical University Innsbruck, Department of Internal Medicine I | Medical University Innsbruck, Department of Neurology, Innsbruck 6020, Austria | Medical University of Innsbruck | Medical University of Innsbruck, Deparmtment of Internal Medicince I | Medizinische Universitaet Innsbruck | MUI, Department of Anaesthesiology and Critical Care Medicine | Universitätsklinik Innsbruck, Universitätsklinik für Neurochirurgie | University Hospital for Neurosurgery Innsbruck | University Hospital for Visceral, Transplant and Thoracic Surgery | University Hospital Innsbruck, Austria | University Hospital Innsbruck, Dept. of General- and Transplant Surgery, Anichstrasse 35, A-6020 Innsbruck | University Hospital Innsbruck, Internal Medicine | University of Innsbruck | University of Innsbruck / Department of Mechatronics | Volker Wenzel | Wolfgang-Michael Franz

Active Ingredients

Drugs in Phase 4 Trials (19)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (2 trials)

apremilast (otezla) (1 trial)

aripiprazole (abilify) (1 trial)

bupropion (wellbutrin) (1 trial)

cetuximab (erbitux) (4 trials)

dapagliflozin (farxiga) (1 trial)

dexamethasone (1 trial)

dinoprostone (prostin e2) (1 trial)

fentanyl (Innovar) (1 trial)

fluorouracil (efudex) (2 trials)

mitomycin (mutamycin) (1 trial)

nitrous oxide (1 trial)

paliperidone (invega) (1 trial)

platelets (1 trial)

propofol (diprivan) (1 trial)

remifentanil (ultiva) (1 trial)

ropivacaine (naropin) (2 trials)

sevoflurane (ultane) (1 trial)

sodium chloride (3 trials)

Drugs in Phase 3 Trials (27)

alemtuzumab (campath) (2 trials)

bevacizumab (avastin) (3 trials)

blood plasma (1 trial)

candesartan (atacand) (1 trial)

chloroquine (1 trial)

clazakizumab (1 trial)

ertugliflozin (Steglatro) (1 trial)

esketamine (spravato) (1 trial)

factor xiii concentrate (human) (Corifact) (1 trial)

fibrinogen (human) (RiaSTAP) (2 trials)

flebosten (1 trial)

human factor ix complex (prothrombin complex concentrate) (Kcentra) (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

icosapent ethyl (vascepa) (1 trial)

imatinib (gleevec) (1 trial)

imiquimod (aldara) (2 trials)

levosimendan (2 trials)

lopinavir (Kaletra) (1 trial)

nabilone (cesamet) (2 trials)

ranibizumab (lucentis) (1 trial)

ritonavir (Norvir) (1 trial)

rivaroxaban (xarelto) (1 trial)

sitagliptin (januvia) (1 trial)

tacrolimus (prograf) (1 trial)

vas203 (1 trial)

vasopressin (vasostrict) (1 trial)

vitamin d3 (1 trial)

Drugs in Phase 2 Trials (29)

68ga-neobomb1 (1 trial)

argatroban (1 trial)

autologous culture chondrocytes (Carticel) (1 trial)

bnt162b2 (1 trial)

bortezomib (velcade) (1 trial)

buprenorphine (1 trial)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (2 trials)

cy-503 (1 trial)

docetaxel (taxotere) (2 trials)

doxorubicin (Doxil) (2 trials)

epoetin (Epogen) (1 trial)

ganetespib (1 trial)

gemcitabine (gemzar) (1 trial)

infliximab (remicade) (1 trial)

irinotecan (Camptosar) (1 trial)

lenalidomide (revlimid) (1 trial)

lenvatinib (lenvima) (1 trial)

lintuzumab (1 trial)

nicardipine (cardene) (1 trial)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (2 trials)

panitumumab (vectibix) (1 trial)

pazopanib (votrient) (1 trial)

pembrolizumab (keytruda) (1 trial)

rasagiline (azilect) (1 trial)

sodium phosphate (1 trial)

sunitinib (sutent) (2 trials)

vaxzevria (1 trial)

Drugs in Phase 1 Trials (4)

111in-cp04 (1 trial)

affitope pd03a (1 trial)

gelofusin (1 trial)

probiotic (1 trial)

Drugs in Other Trials (3)

pamidronate (aredia) (1 trial)

sorafenib (nexavar) (1 trial)

zoledronic acid (zometa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 2)

Aneurysm (Phase 2)

Arthritis (Phase 4)

Arthritis, Psoriatic (Phase 4)

Atrophy (Phase 2)

Blood Coagulation Disorders (Phase 3)

Brain Diseases (Phase 2)

Brain Injuries (Phase 3)

Brain Injuries, Traumatic (Phase 3)

Brain Ischemia (Phase 2)

Bunion (Phase 4)

Carcinoma (Phase 4)

Carcinoma in Situ (Phase 3)

Carcinoma, Neuroendocrine (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Squamous Cell (Phase 4)

Cervical Intraepithelial Neoplasia (Phase 3)

Colorectal Neoplasms (Phase 2)

Coronavirus Infections (Phase 3)

Critical Illness (Phase 2)

Diabetes Mellitus, Type 1 (Phase 4)

Diabetic Foot (Phase 3)

Endometrial Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Gastrointestinal Stromal Tumors (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Hallux Valgus (Phase 4)

Head and Neck Neoplasms (Phase 4)

Heart Failure (Phase 3)

Hemangiosarcoma (Phase 2)

Hemorrhage (Phase 2)

Hemostatic Disorders (Phase 3)

Hypovolemia (Phase 3)

Hypoxia (Phase 2)

Hypoxia-Ischemia, Brain (Phase 2)

Inflammation (Phase 1)

Intervertebral Disc Degeneration (Phase 2)

Intervertebral Disc Displacement (Phase 2)

Ischemia (Phase 2)

Leukemia (Phase 3)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 3)

Macular Degeneration (Phase 3)

Mastodynia (Phase 4)

Multiple System Atrophy (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 3)

Neurodegenerative Diseases (Phase 1)

Opioid-Related Disorders (Phase 2)

Ovarian Neoplasms (Phase 2)

Papillomavirus Infections (Phase 3)

Parkinson Disease (Phase 3)

Peritoneal Neoplasms (Phase 2)

Preleukemia (Phase 2)

Proctitis (Phase 3)

Schizophrenia (Phase 4)

Shock (Phase 3)

Shock, Hemorrhagic (Phase 3)

Shy-Drager Syndrome (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 4)

Subarachnoid Hemorrhage (Phase 2)

Substance-Related Disorders (Phase 4)

Syndrome (Phase 2)

Thrombosis (Phase 4)

Thyroid Diseases (Phase 1)

Thyroid Neoplasms (Phase 1)

Tobacco Use Disorder (Phase 4)

Uterine Cervical Neoplasms (Phase 2)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 60
  • # of Trial APIs: 82